Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-11-19

Clinical Trial Update: Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is evaluating sildenafil to prevent and reduce cancer-related cognitive impairment; the study status indicates not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING